Mike Sathekge, MBChB, University of Pretoria, Pretoria, South Africa, outlines the evolving landscape of PSMA theranostics over the next five years. He emphasizes a shift beyond lutetium-PSMA toward combination strategies involving diverse isotopes, PARP inhibitors, and hormonal therapies, with a focus on better understanding and targeting under-researched disease subtypes such as neuroendocrine prostate cancer. Prof. Sathekge discusses the need for refined patient stratification through translational research and advanced imaging, including the use of DLL3 and radiolabelled PARP-1 inhibitors. He also envisions innovative treatment approaches, such as ablating micrometastatic disease post-surgery using alpha-emitting agents like actinium-225 PSMA. This interview was recorded at the 2025 European Association of Urology (EAU) Congress in Madrid, Spain.
All content is owned by Magdalen Medical Publishing (MMP) and protected under international copyright laws. All rights reserved.
